75 related articles for article (PubMed ID: 20535787)
1. Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis.
Racunica T; Cassidy D; Cicuttini F; Hall A
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):770-4. PubMed ID: 20535787
[No Abstract] [Full Text] [Related]
2. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
3. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians.
Perlmutter A; Mittal A; Menter A
Br J Dermatol; 2009 Jan; 160(1):8-15. PubMed ID: 19016693
[TBL] [Abstract][Full Text] [Related]
4. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
5. Tumor necrosis factor blockers and reactivation of latent tuberculosis.
Keane J
Clin Infect Dis; 2004 Aug; 39(3):300-2. PubMed ID: 15306994
[No Abstract] [Full Text] [Related]
6. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
7. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
8. Treatment of latent tuberculosis infection.
De Rosa FG; Craven DE
N Engl J Med; 2003 Mar; 348(13):1292-3; author reply 1292-3. PubMed ID: 12661576
[No Abstract] [Full Text] [Related]
9. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
10. Differential response of psoriatic onycho-pachydermo-periostitis to 2 anti-tumor necrosis factor-alpha agents.
Kapusta MA; Dumont C
J Rheumatol; 2008 Oct; 35(10):2077-80. PubMed ID: 18843767
[No Abstract] [Full Text] [Related]
11. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
12. Infliximab (Remicade) adn etanercept (Enbrel): serious infections and tuberculosis.
Dunlop H
CMAJ; 2004 Oct; 171(8):992-3. PubMed ID: 15497208
[No Abstract] [Full Text] [Related]
13. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
[No Abstract] [Full Text] [Related]
14. Tuberculosis cases associated with infliximab and etanercept.
Winthrop KL; Siegel JN
Clin Infect Dis; 2004 Oct; 39(8):1256-7. PubMed ID: 15486859
[No Abstract] [Full Text] [Related]
15. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
16. Tuberculosis and treatment with infliximab.
Riminton S; Pearce N; Antony B
N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859879
[No Abstract] [Full Text] [Related]
17. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
18. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
Lahita RG; Vernace MA
J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
[No Abstract] [Full Text] [Related]
19. Macrophage activation syndrome revealing disseminated tuberculosis in a patient on infliximab.
André V; Liddell C; Guimard T; Tanguy G; Cormier G
Joint Bone Spine; 2013 Jan; 80(1):109-10. PubMed ID: 23286892
[No Abstract] [Full Text] [Related]
20. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
Voulgari PV; Venetsanopoulou AI; Epagelis EK; Alamanos Y; Takalou I; Drosos AA
Ann Rheum Dis; 2007 Feb; 66(2):270-1. PubMed ID: 17068063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
